Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.15 - $170.47
Previous CloseN/A
Volume7.58M
Average Volume (3M)9.24M
Market Cap
$9.93B
Enterprise Value$9.73B
Total Cash (Recent Filing)-$1.06B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 01, 2025EPS Estimate
-3.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.28
Shares Outstanding385,815,900
10 Day Avg. Volume8,372,032
30 Day Avg. Volume9,237,747
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.89
Price to Cash Flow (P/CF)3.80
P/FCF Ratio3.70
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.49
Enterprise Value/Ebitda-2.87
Forecast
1Y Price Target
$47.06Price Target Upside71.81% Upside
Rating ConsensusHold
Number of Analyst Covering19
---
Moderna News
PremiumMarket News
SPY ETF News, 4/25/2025
PremiumMarket News
VOO ETF News, 4/25/2025
PremiumMarket News
VOO ETF News, 4/21/2025
PremiumMarket News
SPY ETF News, 4/18/2025
PremiumMarket News
VOO ETF News, 4/17/2025---
Bulls Say, Bears Say
Bulls Say
Vaccine ApprovalThe company submitted a supplementary BLA for mRESVIA for FDA approval in high-risk adults 18-59 years old using a priority review voucher.
Bears Say
Litigation RisksROIV/ABUS have escalated litigation of lipid nanoparticle patent infringement by pursuing MRNA on its mRNA vaccine sales globally.
Price TargetThe price target for Moderna's stock has been lowered, suggesting a less optimistic outlook on its future performance.
Revenue ProjectionsTotal revenue estimates decrease by 10 to 12%, primarily due to lower sales from mRNA-1083 and mRESVIA.
---
Ownership Overview
18.59% Insiders
19.76% Mutual Funds
0.47% Other Institutional Investors
38.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $23.15 and its highest was $170.47 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $9.93B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is May 01, 2025 which is in 6 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Feb 14, 2025. The company reported -$2.91 earnings per share for the quarter, missing the consensus estimate of -$2.68 by -$0.23.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -3.12.
How many shares outstanding does Moderna have?
Moderna has 385,815,900 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$2.91 in its last earnings report, missing expectations of -$2.68. Following the earnings report the stock price went up 3.352%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
---
Moderna Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$47.06 (71.81% Upside)
$47.06 (71.81% Upside)
Blogger Sentiment
Bullish
MRNA Sentiment 64%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 326.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.40%
12-Months-Change
Fundamentals
Return on Equity
-28.77%
Trailing 12-Months
Asset Growth
-23.25%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc. is a biotechnology company specializing in the development and commercialization of messenger RNA (mRNA) technology-based vaccines and therapeutics. Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna is at the forefront of mRNA research and has a diverse portfolio that includes vaccines for infectious diseases, cancer immunotherapies, and rare diseases. The company's most notable product is its mRNA-based COVID-19 vaccine, which has been pivotal in global vaccination efforts.
---
MRNA Company Deck
---
MRNA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Moderna's earnings call reflected a challenging year with significant revenue declines and net losses. However, the company demonstrated strong cost-saving measures and maintained a substantial cash position. Progress in the product pipeline and operational efficiency goals offer potential for future growth.Read More>---
MRNA Revenue Breakdown
55.16% U.S.
26.36% Rest of World
18.48% Europe
---
MRNA Stock 12 Month Forecast
Average Price Target
$47.06
▲(71.81% Upside)
Technical Analysis
Best Analysts Covering MRNA
1 Year
1 Year Success Rate
8/33 ratings generated profit
1 Year Average Return
-10.94%
reiterated a buy rating 3 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 24.24% of your transactions generating a profit, with an average return of -10.94% per trade.
---